12/17
09:17 am
vcnx
Vaccinex receives delisting notice from Nasdaq, shares down over 49% [Seeking Alpha]
Medium
Report
Vaccinex receives delisting notice from Nasdaq, shares down over 49% [Seeking Alpha]
12/17
09:09 am
vcnx
Vaccinex Announces Receipt of Delisting Notification from Nasdaq [Yahoo! Finance]
High
Report
Vaccinex Announces Receipt of Delisting Notification from Nasdaq [Yahoo! Finance]
12/17
09:00 am
vcnx
Vaccinex Announces Receipt of Delisting Notification from Nasdaq
High
Report
Vaccinex Announces Receipt of Delisting Notification from Nasdaq
11/18
08:35 am
vcnx
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
11/18
08:30 am
vcnx
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Medium
Report
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/7
08:30 am
vcnx
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
Neutral
Report
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
11/5
08:30 am
vcnx
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
Low
Report
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
10/31
10:00 am
vcnx
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain
High
Report
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain
10/24
08:30 am
vcnx
Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024
High
Report
Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024
10/16
05:04 pm
vcnx
Vaccinex files for secondary stock offering [Seeking Alpha]
Medium
Report
Vaccinex files for secondary stock offering [Seeking Alpha]